Schizophrenia Clinical Trial
— SCHIFT
Quality of life (QoL) measurements have become an important way to evaluate the treatments
and care provided to patients with schizophrenia. Understanding determinants of QoL in
schizophrenia is of importance for developing effective interventions that would improve
patient functional and subjective well-being. A challenge in the interpretation of QoL
measures, especially in longitudinal studies, is that QoL is self-reported by the patient
and might be influenced by psychological phenomena such as adaptation to illness. An
important mediator of this adaptation process is a "response shift" (RS), which involves
changing internal standards, values and the conceptualization of QoL. RS can be divided into
three phases 1) reconceptualization (i.e., a redefinition of QoL), 2) reprioritization
(i.e., a change in the importance attributed to component domains constituting QoL) and 3)
recalibration (i.e., a change in a patient's internal standards of measurements). Patients
may change their frame of reference, rendering scores from different measurement occasions
incomparable. An RS is a potential explanation when the QoL of an individual who has
experienced a serious health event or chronic condition is similar to the QoL of a healthy
individual. With an RS, the concept of QoL changes over time and cannot be compared
longitudinally because of changes in internal standards, values, and/or concepts. True
change may be over- or underestimated when a RS is present, leading to biased estimates of
the magnitude of change.The objective is to examine whether a response shift, a change in
the internal standards of a patient, occurs in patients suffering from schizophrenia and in
their caregivers.
This is a monocentric and propective design study, with inclusion of patients and caregivers
on a 12-month period, and a follow up on a 12-month period.
100 patients with schizophrenia and 100 caregivers
Test approach (Response shift (RS) (pre-test - then-test), unadjusted effect (post-test -
pre-test), and adjusted effect (post-test - then-test scores)) will be completed with other
statistical approaches such as confirmatory factorial analysis, multilevel models and CART
method.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | January 2017 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria Caregiver:: - Person identified by the patient as the family member or friend who provided the most support or assistance, - Informed consent obtained - Being a native French speaker Inclusion criteria patients: - Suffering of schizophrenia according DSM IV, - Informed consent obtained - Being a native French speaker Exclusion Criteria: - Patient suffuring of demencia |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hôpitaux de Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numbers of response shift occuring in patients suffering from schizophrenia and in their caregivers | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |